Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Drug Royalty Corp., TPL Phytogen Inc., Peptide, Dura deal

DRI will provide C$1.5 million to further TPL's development of paclitaxel, a naturally occurring cancer compound

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE